Oramed Pharmaceuticals (ORMP) Income from Non-Controlling Interests (2012 - 2025)
Oramed Pharmaceuticals' (ORMP) quarterly Income from Non-Controlling Interests came in at -$6000.0 in Q3 2025, up 73.91% YoY from -$3450.0 in Q3 2024, and up 78.57% on a QoQ basis from -$28000.0 in Q2 2025.
Oramed Pharmaceuticals (ORMP) Income from Non-Controlling Interests (2012 - 2025) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 12 years of Income from Non-Controlling Interests data on file, last reported at -$6000.0 in Q3 2025.
- Quarterly Income from Non-Controlling Interests rose 73.91% year-over-year to -$6000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$44000.0 (down 2.33% YoY) and the FY2025 annual result came in at -$34000.0, up 20.93% from the prior year.
- Income from Non-Controlling Interests improved to -$6000.0 in Q3 2025, from -$28000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $834000.0 in Q4 2023 to a low of -$751000.0 in Q3 2021.
- A 5-year average of -$132533.3 and a median of -$62000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests soared 242.08% — and 2025, when it slumped 250.0%.
- Tracing ORMP's Income from Non-Controlling Interests over 5 years: stood at -$751000.0 in 2021, then rose by 21.84% to -$587000.0 in 2022, then soared by 242.08% to $834000.0 in 2023, then plunged by 101.2% to -$10000.0 in 2024, then jumped by 40.0% to -$6000.0 in 2025.
- The last three Income from Non-Controlling Interests figures came in at -$6000.0 (Q3 2025), -$28000.0 (Q2 2025), and -$10000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Dec 31, 2024 | -10,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | 834,000.00 |
| Sep 30, 2023 | -62,000.00 |
| Jun 30, 2023 | -119,000.00 |
| Mar 31, 2023 | -216,000.00 |
| Dec 31, 2022 | -587,000.00 |
| Sep 30, 2022 | -193,000.00 |
| Jun 30, 2022 | -534,000.00 |
| Mar 31, 2022 | -283,000.00 |
| Aug 31, 2021 | -751,000.00 |
| Aug 31, 2018 | 504,000.00 |
| May 31, 2018 | -115,000.00 |
| Feb 28, 2018 | -414,000.00 |
| Nov 30, 2017 | 326,000.00 |
| Aug 31, 2017 | -96,000.00 |